[ad_1]
TUCSON, Ariz., June 08, 2022 (Globe NEWSWIRE) — HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a everyday living science enterprise advancing precision medicine by means of its revolutionary transcriptome-extensive profiling engineering, declared that it will be sponsoring a keynote presentation at the 7th Annual MarketsandMarkets Biomarker and Companion Diagnostics Meeting in San Diego, CA, titled “Implementing Biomarker System in Clinical Trials” on June 16th at 9:05 AM PT.
This presentation will function Chetan Deshpande, Director, Biomarker Clinical Assay Lead, International Products Progress at Pfizer. Mr. Deshpande will examine the problems that are normally faced in clinical trials and how Pfizer has leveraged HTG’s proprietary gene expression profiling HTG EdgeSeq know-how in numerous clinical trials to get over these issues.
Aspects of the Keynote Presentation are down below:
About HTG:
HTG is accelerating precision medicine from analysis to treatment method by harnessing the electric power of transcriptome-large profiling to travel translational analysis, medical diagnostics and specific therapeutics across a assortment of illness places.
Constructing on extra than a decade of groundbreaking innovation and partnerships with biopharma leaders and big educational institutes, HTG’s proprietary RNA platform technologies are built to make the enhancement of life science equipment and diagnostics much more helpful and efficient and to unlock a differentiated and disruptive strategy to transformative drug discovery. For much more details visit www.htgmolecular.com.
HTG Trader Get in touch with:
Ashley Robinson
LifeSci Advisors
Mobile phone: (617) 430-7577
E mail: [email protected]
[ad_2]
Source link
